Evidence map›Paper›PMID 36998152›Full record

ArticleObesity (Silver Spring, Md.)2023

Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence.

Natia Murvelashvili, Luyu Xie, Jeffrey N Schellinger, M Sunil Mathew, Elisa Morales Marroquin, Ildiko Lingvay, Sarah E Messiah, Jaime P Almandoz

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Obesity (Silver Spring, Md.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 8 pooled it
22.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 8 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Article
  11. Review
  12. Review
  13. Article
  14. Impact of preoperative and postoperative anti-obesity medications on early postoperative body mass index reduction after sleeve gastrectomy in pediatrics.Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2026
    Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Natia MurvelashviliDepartment of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA.
Luyu XieUniversity of Texas Health Science Center, School of Public Health, Dallas, Texas, USA.ORCID 0000-0003-4499-0555
Jeffrey N SchellingerDepartment of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA.
M Sunil MathewUniversity of Texas Health Science Center, School of Public Health, Dallas, Texas, USA.
Elisa Morales MarroquinUniversity of Texas Health Science Center, School of Public Health, Dallas, Texas, USA.
Ildiko LingvayDepartment of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0001-7006-7401
Sarah E MessiahUniversity of Texas Health Science Center, School of Public Health, Dallas, Texas, USA.ORCID 0000-0001-6685-2175
Jaime P AlmandozDepartment of Internal Medicine, Division of Endocrinology, UT Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0002-0462-0843
Southwestern Medical Center · USUniversity of Texas Health Science Center at Dallas · US

Funding

UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jeff G McDonald · 2022 to 2026
$7.4M
Socioecological Factors Associated with Ethnic Disparities in Bariatric Surgery Utilization - Diversity Supplement R01MD011686R01MD011686 · NIMHD · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MESSIAH, SARAH ELIZABETH · 2018 to 2023
$3.6M
NIDDK NIH HHS P30 DK127984NIMHD NIH HHS R01 MD011686
6 · The paper itself

Abstract

objectiveThe aim of this study was to compare the effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery (MBS) weight recurrence.

methodsA retrospective analysis of 207 adults with post-MBS weight recurrence treated with semaglutide 1.0 mg weekly (n = 115) or liraglutide 3.0 mg daily (n = 92) at an academic center from January 1, 2015, through April 1, 2021, was conducted. The primary end point was percentage body weight change at 12 months of treatment with regimens containing semaglutide or liraglutide.

resultsThe mean sample age was 55.2 years; mean BMI was 40.4 kg/m

conclusionsThese results show that treatment regimens including semaglutide 1.0 mg weekly lead to superior weight loss compared with liraglutide 3.0 mg daily for treating post-MBS weight recurrence, regardless of procedure type or the magnitude of weight recurrence.

Indexed as

Bariatric SurgeryGlucagon-Like PeptidesLiraglutideObesity, MorbidWeight GainAdultFemaleHumansHypoglycemic AgentsMaleMiddle AgedPostoperative PeriodRetrospective StudiesSemaglutideTreatment OutcomeWeight LossGlucagon-Like PeptidesHypoglycemic AgentsLiraglutideSemaglutide

Identifiers

PMID36998152
PMCPMC12398307
OpenAlexW4362458746

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.